CoChat

Pulmonary hypertension in chronic lung disease and hypoxia

Open access
Nathan, Steven D., Barbera, Joan A., Gaine, Sean P., Harari, Sergio, Martinez, Fernando J., Olschewski, Horst, Olsson, Karen M., Peacock, Andrew J., Pepke-Zaba, Joanna, Provencher, Steeve, Weissmann, Norbert, Seeger, Werner · 2019 · European Respiratory Journal

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Abstract

Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.01914-2018

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Evaluation of pulmonary hypertension (PH) in chronic lung disease (CLD). FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; CT: computed tomography; PAH: pulmonary arterial hypertension; RCT: randomised controlled trial; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide. #: suggestive findings include: 1) symptoms and signs (dyspnoea out of proportion, loud P2, signs of right heart failure, right axis deviation on ECG, elevated natriuretic peptide levels); 2) pulmonary function test abnormalities (low DLCO (e.g. <40% of predicted), elevated %FVC/%DLCO ratio (low KCO)); 3) exercise test findings (including decreased distance, decreased arterial oxygen saturation or increased Borg rating on 6-min walk test and decreased circulatory reserve, preserved ventilatory reserve on cardiopulmonary exercise testing); and 4) imaging findings (extent of LD, enlarged pulmonary artery segments, increased pulmonary artery/aorta diameter ratio >1 on CT). ¶: signs supporting the diagnosis of PH include elevated systolic pulmonary arterial pressure and signs of right ventricular dysfunction. However, echocardiography measures are only suggestive and have limited accuracy in patients with CLD. +: strongly consider referring the patient to a PH expert centre. §: expert centres should comprise multidisciplinary teams. Any decision for individualised treatment should follow a goal-orientated approach with predefined treatment targets, to be stopped if these targets are not met after a predefined time period.
FIGURE 1 Evaluation of pulmonary hypertension (PH) in chronic lung disease (CLD). FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; CT: computed tomography; PAH: pulmonary arterial hypertension; RCT: randomised controlled trial; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide. #: suggestive findings include: 1) symptoms and signs (dyspnoea out of proportion, loud P2, signs of right heart failure, right axis deviation on ECG, elevated natriuretic peptide levels); 2) pulmonary function test abnormalities (low DLCO (e.g. <40% of predicted), elevated %FVC/%DLCO ratio (low KCO)); 3) exercise test findings (including decreased distance, decreased arterial oxygen saturation or increased Borg rating on 6-min walk test and decreased circulatory reserve, preserved ventilatory reserve on cardiopulmonary exercise testing); and 4) imaging findings (extent of LD, enlarged pulmonary artery segments, increased pulmonary artery/aorta diameter ratio >1 on CT). ¶: signs supporting the diagnosis of PH include elevated systolic pulmonary arterial pressure and signs of right ventricular dysfunction. However, echocardiography measures are only suggestive and have limited accuracy in patients with CLD. +: strongly consider referring the patient to a PH expert centre. §: expert centres should comprise multidisciplinary teams. Any decision for individualised treatment should follow a goal-orientated approach with predefined treatment targets, to be stopped if these targets are not met after a predefined time period.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 834

Metadata

Authors
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., Weissmann, N., & Seeger, W.
Affiliations
  • Inova Fairfax Hospital (US)
  • MultiMedica (IT)
  • Medical University of Graz (AT)
  • Medizinische Hochschule Hannover (DE)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Justus-Liebig-Universität Gießen (DE)
Venue
European Respiratory Journal
Published
2019-01
Volume
53
Issue
1
Pages
1801914
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2904463477
Cited by
757
References
94
Citations by year
2026: 54 · 2025: 104 · 2024: 141 · 2023: 96 · 2022: 122 · 2021: 114 · 2020: 76 · 2019: 44
FWCI
10.56
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Respiratory Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc)
Funders
  • American Thoracic Society
  • Pfizer
  • AstraZeneca
  • Bayer
  • GlaxoSmithKline
  • Gilead Sciences
  • Biogen
  • Teva Pharmaceutical Industries
  • United Therapeutics Corporation
  • Sunovion
  • Veracyte
  • York University
  • National Institutes of Health
  • Genentech
  • Actelion Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
pulmonary hypertension, chronic lung disease, hypoxia, hemodynamic assessment, quality of life, mortality risk, oxygen requirement
MeSH terms
Animals, Hypoxia, Antihypertensive Agents, Chronic Disease, Humans, Hypertension, Pulmonary, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.